Alseroxylon
Pharmaceutical drug
N
Y (what is this?) (verify) Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension[1] and angina pectoris and as a sedative in psychoses.[2] It was at one time approved for use in the United States, but has since been discontinued.[3]
Alseroxylon is a purified fat-soluble extract of the root of Rauvolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids.[2]
References
- ^ Green RS, Davolos D (May 1956). "A long-term study of the effect of crude Rauwolfia serpentina and of its alseroxylon fraction in patients with hypertension". The American Journal of Medicine. 20 (5): 760–73. doi:10.1016/0002-9343(56)90158-9. PMID 13313574.
- ^ a b DrugBank DB00386
- ^ Approved Drug Products with Therapeutic Equivalence Evaluations (33rd ed.). 2013.
{{cite book}}:|work=ignored (help)
- v
- t
- e
Monoamine reuptake inhibitors
(DRIsTooltip Dopamine reuptake inhibitors)
(NRIsTooltip Norepinephrine reuptake inhibitors)
(SRIsTooltip Serotonin reuptake inhibitors)
- Amiodarone
- Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
- APP
- AZIK
- Bietaserpine
- Deserpidine
- Deutetrabenazine
- Dihydrotetrabenazine
- Efavirenz
- GBR-12935
- GZ-793A
- Ibogaine
- Ketanserin
- Lobeline
- Methoxytetrabenazine
- Reserpine
- Rose bengal
- Tetrabenazine
- Valbenazine
- Vanoxerine (GBR-12909)
- DAT enhancers: Luteolin
- DAT modulators: Agonist-like: SoRI-9804
- SoRI-20040; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
